The diabetic neuropathy market study by Fact.MR offers compelling insights into key growth drivers and restraints impacting the market through 2031.
Expanding at 5.9% CAGR, Peripheral Neuropathy to Cement Dominance in Diabetic Neuropathy Treatment Market
The diabetic neuropathy market study by Fact.MR offers compelling insights into key growth drivers and restraints impacting the market through 2031. The survey offers diabetic neuropathy demand outlook and studies opportunities existing in key segments, including type and end user. It also highlights key strategies adopted by market players to increase diabetic neuropathy sales.
Fact.MR – A Market Research and Competitive Intelligence Provider: As per the insights by Fact.MR, the global market for diabetic neuropathy is anticipated to rise at a CAGR of 5.6% over the forecast period 2021-2031.
Increasing prevalence of diabetes as a result of changing lifestyles and imbalanced diets is a primary factor, supporting the growth of the diabetic neuropathy market. In 2019, it was found that over 1/10th of the world’s population suffered from diabetes.
Considering this, leading manufacturers are increasingly focusing on incorporating anti-diabetic formulations within their diversified portfolio. For instance, Janssen Global Services LLC, a leading pharmaceutical company offers a wide range of drugs including NUCYNTA, NUCYNTA ER, Duragesic and INVOKANA.
These drugs include tapentadol and canagliflozin, which help in regulating the blood sugar levels. Several other leading pharmaceutical companies are expected to join the bandwagon, while expanding their portfolio. These factors will contribute towards the growth of the diabetic neuropathy market.
Request a report sample to gain comprehensive insights at
https://www.factmr.com/connectus/sample?flag=S&rep_id=4698
Among various types of disorders, peripheral neuropathy segment is gaining traction and exhibiting a higher sales of diabetic neuropathy formulations. As per the Fact.MR, demand outlook for peripheral neuropathy remains optimistic and it is set to expand at a CAGR of 5.9% over the upcoming years.
Besides these, hospitals have emerged as dominant end users owing to the availability of advanced infrastructure and healthcare expertise. Also higher footfall patients will continue supporting growth in demand across hospitals.
According to the study, North America is dominating the market for diabetic neuropathy, accounting for nearly 2/5 of the market revenue across the globe. Owing to factors such as increasing number of patients for getting treatment along with rising investment in research for the development of new drugs, the market in the region is expected to expand considerably over the forecast period 2021-2031.
“Increasing emphasis on research and development pursuits along with innovations in drug combinations for fulfilling the dual purpose of providing symptomatic pain relief and preventing the progression of neuropathic processes will bolster future growth prospects,” says a Fact.MR analyst.
Key Takeaways from Diabetic Neuropathy Market Survey
- North America will emerge as a dominant market, expanding by 1.4X through the forecast period
- Asia Pacific is expected to emerge as a highly lucrative pocket, accounting for 1/5 of the global market share and expanding at 1.5X over the forecast period.
- Based on disorder, proximal neuropathy is anticipated to grow at a CAGR of 5.6% by the end of 2031.
Key Drivers
- Increasing prevalence of diabetes is propelling growth of the diabetic neuropathy market.
- Launch of novel products likely to influence growth of the diabetic neuropathy market.
Key Restraints
- High cost of drugs used for the treatment of diabetic neuropathy is expected to hamper the market growth.
- Increasing availability of alternative treatments is also a major factor restraining growth of the market.
To learn more about Diabetic Neuropathy Market, you can get in touch with our Analyst at:
https://www.factmr.com/connectus/sample?flag=AE&rep_id=4698
Competitive Landscape
Diabetic neuropathy manufacturers are focusing on receiving certifications from international organizations for their new product launches.
In 2017, Pfizer announced that the U.S. Food and Drug Administration (FDA) approves STEGLATRO™ (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN™ (ertugliflozin and sitagliptin) tablets
For instance, in 2020, Lupin Pharmaceuticals Inc, received tentative approval from U.S. health regulator to market type 2 diabetes drugs namely Empagliflozin and Linagliptin tablets.
Some of the leading players operating in the diabetic neuropathy market profiled by Fact.MR are:
- DAIICHI SANKYO COMPANY
- LIMITED
- Eli Lilly and Company
- Johnson and Johnson Services
- Inc.
- Novartis AG
- Pfizer Inc.
More Valuable Insights on Diabetic Neuropathy Market
Fact.MR, in its new report, offers an unbiased analysis of the global diabetic neuropathy market, analysing forecast statistics through 2021 and beyond. The survey reveals growth projections on diabetic neuropathy market with detailed segmentation:
- Disorder
- Peripheral Neuropathy
- Autonomic Neuropathy
- Proximal Neuropathy
- Focal Neuropathy
- Treatment
- Drugs:
- Analgesic:
- Topical:
- Capsaicin
- Others
- Opioid:
- Morphine
- Others
- NSAIDs:
- Ibuprofen
- Naproxen
- Others
- Antidepressants:
- TCAs:
- Amitriptyline
- Imipramine
- Others
- SNRIs:
- Duloxetine
- Others
- SSRIs:
- Citalopram
- Paroxetine
- Others
- TCAs:
- Anticonvulsant Drugs:
- Gabapentin
- Pregabalin
- Topiramate
- Others
- Other Drugs
- Radiotherapy:
- Transcutaneous Electrical Nerve Stimulation (TENS)
- Others
- Physiotherapy
- Distribution Channel
- Hospitals
- Clinics
- Retail Pharmacy
- Online Pharmacy
- Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa (MEA)
Key Questions Covered in the Diabetic Neuropathy Market Report
- The market survey also highlights projected sales growth for diabetic neuropathy market between 2021 and 2031
- The report offers insight into diabetic neuropathy demand outlook for forecast period 2021-2031
- Diabetic neuropathy market share analysis of the key companies within the industry and coverage of strategies such as mergers & acquisitions, collaborations or partnerships, and others
- Diabetic neuropathy market analysis identifies key growth drivers, restraints, and other forces impacting prevailing trends and evaluation of current market size and forecast and technological advancements within the industry
Explore Fact.MR’s Coverage on the Healthcare Domain –
Diabetes Diagnostics Market- The demand for diabetes diagnostics is predicted to increase as a result of the COVID-19 outbreak, which has resulted in an increase in hospitalizations. Diabetes test strips are in high demand as a result of studies that show diabetics are at a higher risk of becoming seriously ill if infected with the virus. Government investment for hospitals will help to expand the market overall by making healthcare more accessible in remote areas. The diabetes diagnostics industry will see further growth as the prevalence of obesity rises. Through 2030, the global diabetes diagnostics market will be dominated by players from North America, Asia Pacific, and Europe.
Diabetes Management Software Market- The rising prevalence of type 1 and type 2 diabetes is one of the factors driving the growth of the diabetes management software industry. Diabetes patients are growing as a result of unhealthy lifestyles, poor diets, and rising stress and tensions. As a result, in recent years, the adoption of diabetes management software has increased, resulting in a favourable impact on the diabetes management software market. Another factor driving the growth of the diabetes management software market is technological advancements. One of the most important elements driving the remarkable development in the use of diabetes management software is the increasing number of younger diabetics.
OTC Analgesics Market- Over the last few years, there has been an increase in the use of off-label medications, which are inexpensive and unapproved but effective in treating ailments. Off-label medications such as tricyclic antidepressants, antihistamines, anticonvulsants, selective serotonin reuptake inhibitors, anti-anxiety medicines, and steroids are increasingly being used to treat pain sensations. Because of the widespread availability of over-the-counter analgesics, which are administered with approved medications as maintenance therapy, symptom management linked with pain has become convenient and straightforward. The market for over-the-counter analgesics has shown to have a lot of potential all over the world.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analysed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
Mahendra Singh
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Source: Fact.MR